Chemistry:LIT-002

From HandWiki

LIT-002 is a small-molecule oxytocin receptor agonist which is under investigation for potential medical use, with possible indications including autism, drug addiction, and neuropathic pain.[1][2][3][4][5]

Pharmacology

Pharmacodynamics

LIT-002 is a highly potent full agonist of the oxytocin receptor, with an EC50 of 0.15 nM.[1][2][3][4] It is an improved analogue of the earlier drug LIT-001, with 300-fold greater potency than LIT-001 and 2.6-fold greater potency than oxytocin as an oxytocin receptor agonist in vitro.[3][4] The drug is the most potent oxytocin receptor agonist described to date.[3] In addition to its oxytocin receptor agonism, LIT-002 is a highly potent agonist of the vasopressin V2 receptor (EC50 = 0.25 nM) and a very weak modulator of the vasopressin V1A and V1B receptors (EC50 = 966 nM and 760 nM, respectively).[3] The drug is more selective for the oxytocin receptor over the vasopressin receptors than LIT-001.[3]

LIT-002 enhances social interaction in multiple models of autism in rodents.[3][4] In addition, it shows robust analgesic effects comparable to those of pregabalin in animal models of neuropathic pain in rodents.[5] The drug did not affect spontaneous locomotor activity, indicating lack of sedation, and its effects in neuropathic pain models were reversed by a centrally active oxytocin receptor antagonist but not by a peripherally restricted oxytocin receptor antagonist.[5] Due to its vasopressin V2 receptor agonism, LIT-002 produces antidiuretic effects.[3] Vasopressin V2 receptor activation can cause hyponatremia and this can potentially be life-threatening.[6][7][8] However, co-administration of urea with LIT-002 can counterbalance its off-target antidiuretic effects, and the effects are described as manageable.[3]

Pharmacokinetics

LIT-002 is orally active in rodents.[3][5] The drug's pharmacokinetics, for instance blood–brain barrier permeability, are not fully optimal, but it is nonetheless centrally active and with high potency.[3][4] Small-molecule oxytocin receptor agonists like LIT-001 and LIT-002 have greatly improved pharmacokinetic and drug-like properties compared to oxytocin itself.[3]

Chemistry

The chemical synthesis of LIT-002 has been described.[3][2] Various analogues of LIT-002 such as LIT-001 among others have been described.[3][2][9][10][11]

History and development

LIT-002 was patented in 2024[2] and was first described in the scientific literature by 2026.[3][4][5] It was developed by Marcel Hibert and colleagues at the Laboratory for Therapeutic Innovation (LIT) at the University of Strasbourg in France and by the Centre National de la Recherche Scientifique (CNRS; French National Centre for Scientific Research).[1][2][3] The drug is now being developed by the startup pharmaceutical company Occentis Pharmaceuticals.[1][3] Potential therapeutic applications of LIT-002 include treatment of autism, alcoholism, opioid addiction, and neuropathic pain.[1][3][4][5][12]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "De l'amour au traitement de l'autisme : une histoire d'ocytocine" (in fr). 15 December 2025. https://lejournal.cnrs.fr/nos-blogs/matieres-a-penser/de-lamour-au-traitement-de-lautisme-une-histoire-docytocine. "Ce n’est que très récemment que nous avons identifié un composé répondant aux critères attendus. Ce produit, le LIT-002, est plus puissant que l’ocytocine elle-même, in vitro et in vivo. À des concentrations extrêmement faibles, il améliore l’interaction sociale dans deux modèles animaux d’autisme. La molécule et ses analogues ont été brevetés56, et les brevets ont été licenciés par le CNRS et l’Université de Strasbourg pour créer une start-up, Occentis7. Société spécialisée dans le développement de médicaments pour le traitement des maladies neuropsychiatriques et neurocomportementales, elle vise à répondre aux besoins dans des domaines thérapeutiques tels que l'autisme, la dépendance à l'alcool et aux opioïdes, la douleur neuropathique… C’est elle qui prendra en charge les étapes suivantes du développement préclinique et clinique8, ce qui nécessitera comme toujours de 6 à 10 ans avant de pouvoir proposer un médicament aux patients qui le souhaitent." 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Non peptidergic agonists of oxytocin receptor". 30 November 2023. https://patents.google.com/patent/WO2024115660A1/en. 
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 "LIT-002, a highly potent and selective nonpeptide oxytocin receptor agonist that improves social interaction in mouse models of autism". SSRN Electronic Journal. April 2026. doi:10.2139/ssrn.6624262. 
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 "LIT-002, A Highly Potent and Selective Nonpeptide Oxytocin Receptor Agonist That Improves Social Interaction in Mouse Models of Autism". FENS Forum 2026. Barcelona, Spain. 7 July 2026. https://fens2026.abstractserver.com/program/#/details/presentations/3180. 
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 "LIT-002, A Highly Potent and Selective Non-Peptide Oxytocin Receptor Agonist for Durable Relief of Neuropathic Pain". FENS Forum 2026. Barcelona, Spain. 10 July 2026. https://world-wide.org/fens-26/lit-002-highly-potent-selective-non-peptide-46338edb.  Poster.
  6. ↑ "Pathophysiology of Drug-Induced Hyponatremia". J Clin Med 11 (19). September 2022. doi:10.3390/jcm11195810. PMID 36233678. 
  7. ↑ "Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic". J Clin Endocrinol Metab 111 (4): 922–937. March 2026. doi:10.1210/clinem/dgaf651. PMID 41363127. 
  8. ↑ "Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials". JAMA Netw Open 7 (11): e2445278. November 2024. doi:10.1001/jamanetworkopen.2024.45278. PMID 39546312. 
  9. ↑ "Approches moléculaires et thérapeutiques des interactions entre l'ocytocine et son récepteur" (in French). Biologie Aujourd'hui 216 (3–4): 125–130. 2022. doi:10.1051/jbio/2022013. PMID 36744978. 
  10. ↑ "Novel Nonpeptide as Oxytocin Receptor Agonist". ACS Med Chem Lett 16 (5): 750–751. May 2025. doi:10.1021/acsmedchemlett.5c00191. PMID 40365388. 
  11. ↑ "Novel Tetrahydrobenzo[bpyrazolo[3,4-e][1,4]diazepine Compounds as Oxytocin Receptor Agonists for Treating Autism Spectrum Disorders"]. ACS Med Chem Lett 16 (5): 752–753. May 2025. doi:10.1021/acsmedchemlett.5c00190. PMID 40365400. 
  12. ↑ "LIT-002 is strong candidate for autism and neuropathic pain". 17 July 2026. https://www.bioworld.com/articles/732709-lit-002-is-strong-candidate-for-autism-and-neuropathic-pain?v=preview. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:LIT-002&oldid=4582709"